Unknown

Dataset Information

0

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

ABSTRACT: Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neurotoxicity, and DNA repair, which in turn affect CIPN development and severity. Variations of other molecular markers may also affect the incidence and severity of CIPN. Hence, the objective of this review was to summarize the known biological (molecular and genomic) predictors of CIPN and discuss the means to facilitate progress in this field.

SUBMITTER: Chan A 

PROVIDER: S-EPMC6728179 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Chan Alexandre A   Hertz Daniel L DL   Morales Manuel M   Adams Elizabeth J EJ   Gordon Sharon S   Tan Chia Jie CJ   Staff Nathan P NP   Kamath Jayesh J   Oh Jeong J   Shinde Shivani S   Pon Doreen D   Dixit Niharkia N   D'Olimpio James J   Dumitrescu Cristina C   Gobbo Margherita M   Kober Kord K   Mayo Samantha S   Pang Linda L   Subbiah Ishwaria I   Beutler Andreas S AS   Peters Katherine B KB   Loprinzi Charles C   Lustberg Maryam B MB  

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 20190730 10

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and debilitating condition associated with a number of chemotherapeutic agents. Drugs commonly implicated in the development of CIPN include platinum agents, taxanes, vinca alkaloids, bortezomib, and thalidomide analogues. As a drug response can vary between individuals, it is hypothesized that an individual's specific genetic variants could impact the regulation of genes involved in drug pharmacokinetics, ion channel functioning, neu  ...[more]

Similar Datasets

Unknown A systematic summary and comparison of animal models for chemotherapy induced (peripheral) neuropathy (CIPN).
| S-EPMC6713358 | biostudies-literature
Unknown An asymptomatic mutation complicating severe chemotherapy-induced peripheral neuropathy (CIPN): a case for personalised medicine and a zebrafish model of CIPN.
| S-EPMC5685301 | biostudies-literature
Unknown Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH Collaboratory study of claims data.
| S-EPMC7060096 | biostudies-literature
Unknown Chemotherapy-induced peripheral neuropathy (CIPN): current therapies and topical treatment option with high-concentration capsaicin.
| S-EPMC8236465 | biostudies-literature
Unknown Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.
| S-EPMC4879099 | biostudies-literature
Unknown Mangafodipir a Selective Cytoprotectant - with Special Reference to Oxaliplatin and Its Association to Chemotherapy-Induced Peripheral Neuropathy (CIPN).
| S-EPMC5496205 | biostudies-literature
Unknown Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study.
| S-EPMC3669650 | biostudies-literature
Unknown Chemotherapy-induced peripheral neuropathy: longitudinal analysis of predictors for postural control.
| S-EPMC7840973 | biostudies-literature
Unknown Neurological complications of new chemotherapy agents.
| S-EPMC5761528 | biostudies-other
Unknown Pathophysiology of Chemotherapy-Induced Peripheral Neuropathy.
| S-EPMC5450696 | biostudies-literature